← Back to Search

Antibiotic

Antibiotics for Urinary Tract Infections After Bladder Surgery

Phase 4
Waitlist Available
Led By Khurshid A Guru
Research Sponsored by Roswell Park Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Females who receive a fertile sex sparing robot-assisted radical cystectomy (RARC)
Patients with renal dysfunction, creatinine clearance (mL/min) < 30
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 90 days after surgery
Awards & highlights
Drug Has Already Been Approved
No Placebo-Only Group
Pivotal Trial

Summary

This trial is testing whether a month of antibiotics can help reduce urinary infections after surgery to remove the bladder.

Who is the study for?
This trial is for patients planning to undergo robot-assisted surgery to remove the bladder due to muscle-invasive or refractory non-muscle invasive bladder cancer. Participants must understand and consent to the study's nature. Excluded are those with myasthenia gravis, QT prolongation, severe kidney issues, pregnant/nursing women, and anyone who can't follow the protocol.
What is being tested?
The trial tests if a one-month course of antibiotics like trimethoprim-sulfamethoxazole or nitrofurantoin after robot-assisted radical cystectomy reduces urinary tract infections. It aims to improve post-surgery outcomes and manage complications better.
What are the potential side effects?
Possible side effects from antibiotics may include allergic reactions, gastrointestinal upset (like nausea or diarrhea), potential organ inflammation, skin rashes, and increased resistance to antibiotics.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am a woman who had a fertility-preserving bladder surgery.
Select...
My kidney function is low, with a creatinine clearance under 30 mL/min.
Select...
I do not have a history of abnormal heart rhythms nor take medication that affects it.
Select...
I was given antibiotics before leaving the hospital.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 90 days after surgery
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 90 days after surgery for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
90-day urinary tract infection (UTI) status
Secondary study objectives
Development of Clostridium difficile (C Diff)
Identify post operative factors associated with the development of UTI
Identify pre-operative factors associated with the development of UTI
+1 more

Side effects data

From 2014 Phase 3 trial • 607 Patients • NCT00405704
14%
Fever
8%
Rash
6%
Pharyngitis
5%
Viral Infection
4%
Diarrhea
4%
Otitis Media
100%
80%
60%
40%
20%
0%
Study treatment Arm
Trimethoprim-Sulfamethoxazole
Placebo

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Group I (trimethoprim-sulfamethoxazole, nitrofurantoin)Experimental Treatment6 Interventions
Patients receive ertapenem PO, levofloxacin PO, or clindamycin PO induction therapy per standard of care. At the time of full diet, patients receive trimethoprim-sulfamethoxazole PO daily or nitrofurantoin PO daily on days 1-30. Patients complete a drug diary for each day they receive the antibiotic.
Group II: Group II (standard of care)Active Control3 Interventions
Patients receive ertapenem PO, levofloxacin PO, or clindamycin PO induction therapy per standard of care.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Trimethoprim-Sulfamethoxazole
2010
Completed Phase 3
~1260
Nitrofurantoin
2011
Completed Phase 4
~4100
Clindamycin
2017
Completed Phase 4
~14760
Ertapenem
2011
Completed Phase 4
~8070
Levofloxacin
2011
Completed Phase 4
~8180

Find a Location

Who is running the clinical trial?

Roswell Park Cancer InstituteLead Sponsor
414 Previous Clinical Trials
33,633 Total Patients Enrolled
Khurshid A GuruPrincipal InvestigatorRoswell Park Cancer Institute
2 Previous Clinical Trials
117 Total Patients Enrolled

Media Library

Clindamycin (Antibiotic) Clinical Trial Eligibility Overview. Trial Name: NCT04502095 — Phase 4
UTI Research Study Groups: Group II (standard of care), Group I (trimethoprim-sulfamethoxazole, nitrofurantoin)
UTI Clinical Trial 2023: Clindamycin Highlights & Side Effects. Trial Name: NCT04502095 — Phase 4
Clindamycin (Antibiotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04502095 — Phase 4
~17 spots leftby Dec 2025